Malignant lymphoma of bone

Ostrowski, Mary L.; Unni, K. Krishnan; Banks, Peter M.; Shives, Thomas C.; Evans, Richard G.; O’Connell, Michael J.; Taylor, William F.

doi:10.1002/1097-0142(19861215)58:12<2646::aid-cncr2820581217>3.0.co;2-u

Cited by 296 publications

(162 citation statements)

References 6 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…Ewing's sarcoma (including PNET) is the most common intraosseous small round cell tumor, and constitutes approximately 70% of these cases (11), whereas bone lymphomas account for approximately 5% of all primary bone tumors (12)(13)(14). Both of these tumors also may present as primary soft tissue tumors, however, very rarely (15)(16)(17).…”

Section: Discussionmentioning

confidence: 99%

Differentiating Lymphoblastic Lymphoma and Ewing's Sarcoma: Lymphocyte Markers and Gene Rearrangement

et al. 2001

View full text Add to dashboard Cite

We encountered a child with an intraosseous small round cell tumor that was negative for LCA, CD20 (L26), and CD3 and positive for vimentin, CD99 (MIC-2), and periodic acid-Schiff. The tumor exhibited rosette-like formations. This case was initially interpreted as Ewing's sarcoma (ES); however, additional studies revealed positivity for CD79a, CD43, and TdT expression, and an immunoglobulin heavy chain gene rearrangement (IgH-R) by polymerase chain reaction (PCR) established this to be a precursor B-lymphoblastic lymphoma. Because the differential diagnosis of ES and lymphoblastic lymphoma can be difficult and the differential diagnostic value of leukocyte antigens and immunoglobulin heavy chain gene rearrangement studies have not been fully evaluated, we conducted a more extensive investigation on 33 (21 soft tissue and 12 intraosseous) ES cases. Cases were retrieved from the files of the Department of Pathology at Georgetown University and from the Soft Tissue Registry of the Armed Forces Institute of Pathology. The cases were studied by light microscopy, immunohistochemistry, and PCR for IgH-R and T cell receptor gamma chain gene rearrangement (T␥-R). There were 17 females and 16 males; the mean age was 29.3 years. Locations included the extremities (n ‫؍‬ 17) and trunk (n ‫؍‬ 16). All cases fit the ES spectrum by light microscopy and immunohistochemistry, as previously determined, and were negative for lymphoid markers (LCA, CD3, CD20, CD43, CD79a, and TdT), CD10 and CD34. CD99 was positive in 31/33 and bcl-2 was weakly positive in 13/33 cases. All 21 cases studied for gene rearrangements by PCR were negative for IgH-R and T␥-R. Distinction of intraosseous lymphoblastic lymphoma from ES may be difficult because lymphomas may occasionally exhibit unexpected morphologic and immunophenotypic properties including LCA, CD3 and CD20 negativity and cytokeratin positivity. Additional analysis using CD79a, CD43, TdT, and PCR should be performed to avoid misdiagnosis. True ES is negative for lymphoid markers including CD79a, CD43, and TdT, as well as for IgH-R and T␥-R.

show abstract

Section: Discussionmentioning

confidence: 99%

Differentiating Lymphoblastic Lymphoma and Ewing's Sarcoma: Lymphocyte Markers and Gene Rearrangement

et al. 2001

View full text Add to dashboard Cite

show abstract

“…In the past, the clinical parameters used to predict prognosis in PLB, were tumour stage and localisation. 7,8,10,11 We found these prognostic factors not easily applicable to PLB. Furthermore, as in other extra-nodal lymphomas, in PLB prognosis is not strongly affected by regional lymph node involvement: there was no difference in survival between stage I and stage II tumours and just a trend towards worse prognosis in stage IV tumours.…”

Section: Discussionmentioning

confidence: 83%

“…The group consisted of 39 males and 21 females, a ratio of 1.8 consistent with other studies. 8 The age of the patients varied from 13 to 86 years (median 48). The PLB most often presented in the long bones (29 localisations, 48%), of which seven localisations (12%) presented in the upper limb and 22 localisations (36%) in the lower limb ( Figure 1).…”

Section: Patient Characteristicsmentioning

confidence: 99%

“…In many studies stage IV tumours were excluded and patients were only treated with radiotherapy. [4][5][6][7][8][9][10][11] Uniform directives for classification, treatment and prognosis are still lacking. We describe a relatively large group of 60 patients with clinico-radiologically and histologically documented PLB, collected from the files of the Netherlands Committee on Bone Tumours and the Leiden University Medical Centre.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

True

1999

Leukemia

View full text Add to dashboard Cite

A retrospective analysis of patients presenting with primary lymphoma of bone (PLB) was performed to determine clinical factors affecting prognosis in relation to histological subtype and treatment outcome. Data from 106 patients, presenting with a PLB between 1943 and 1996, were retrieved from the files of the Netherlands Committee on Bone Tumours and Leiden University Medical Centre. The lymphomas were reclassified according to the REAL and updated Kiel classification. The clinical presentation, survival and prognostic factors were investigated. Sixty patients had sufficient clinical information and adequate follow-up to be included in the study. All 33 PLB that could be immunophenotyped were of B cell origin. According to the REAL classification, most PLB were large (B) cell lymphomas (92%) and according to the Kiel classification 45% of the tumours were centroblastic multilobated. PLB presented most often in the long bones (48%), with Ann Arbor stage I (46%), II (16%), IV (16%) and unknown (20%). Stage IV disease was exclusively caused by the presence of multiple bone lesions. Notwithstanding the heterogeneous treatment, the 5-year overall survival was 61%; 46% of patients were progression free at 5 years. Patients at presentation older than 60 had a worse overall survival (76% vs 37%, P ‫؍‬ 0.0002) and a worse progression-free period (58% vs 28%, P ‫؍‬ 0.0073). Patients with the immunoblastic subtype had a worse survival than the centroblastic mono/polymorphic subtype or the centroblastic multilobated subtype (P ‫؍‬ 0.015). Primary lymphoma of bone represents an uncommon bone tumour with a relatively homogeneous morphology and clinical behaviour. Compared to other aggressive lymphomas, PLB have a favourable prognosis.

show abstract

“…Most series have reported that the long bones are affected most frequently (especially the femur), although a large series showed equal numbers of cases presenting in the long bones and the spine. [7][8][9][10][11][12] In order to diagnose primary lymphoma of the bone, it is necessary to exclude nodal or disseminated disease by physical examination and imaging. As plain films are often normal, bone scan or MRI of clinically affected areas is necessary to establish disease extent.…”

Section: Commentarymentioning

confidence: 99%

A pain in the bone

Srour

Bráza

Smetana

2010

Journal of Hospital Medicine

View full text Add to dashboard Cite

The approach to clinical conundrums by an expert clinician is revealed through presentation of an actual patient's case in an approach typical of morning report. Similar to patient care, sequential pieces of information are provided to the clinician who is unfamiliar with the case. The focus is on the thought processes of both the clinical team caring for the patient and the discussant. A 71-year-old man presented to a hospital with a one week history of fatigue, polyuria, and polydipsia. He also reported pain in his back, hips, and ribs, in addition to frequent falls, intermittent confusion, constipation, and a weight loss of 10 pounds over the last 2 weeks. He denied cough, shortness of breath, chest pain, fever, night sweats, headache, and focal weakness.Polyuria, which is often associated with polydipsia, can be arbitrarily defined as a urine output exceeding 3 L per day. After excluding osmotic diuresis due to uncontrolled diabetes mellitus, the 3 major causes of polyuria are primary polydipsia, central diabetes insipidus, and nephrogenic diabetes insipidus. Approximately 30% to 50% of cases of central diabetes insipidus are idiopathic; however, primary or secondary brain tumors or infiltrative diseases involving the hypothalamic-pituitary region need to be considered in this 71-year-old man. The most common causes of nephrogenic diabetes insipidus in adults are chronic lithium ingestion, hypokalemia, and hypercalcemia. The patient describes symptoms that can result from severe hypercalcemia, including fatigue, confusion, constipation, polyuria, and polydipsia.The patient's past medical history included long-standing, insulinrequiring type 2 diabetes with associated complications including coronary artery disease, transient ischemic attacks, proliferative retinopathy, peripheral diabetic neuropathy, and nephropathy. Seven years prior to presentation, he received a cadaveric renal transplant that was complicated by BK virus (polyomavirus) nephropathy and secondary hyperparathyroidism. Three years after his transplant surgery, he developed squamous cell carcinoma of the skin, which was treated with local surgical resection. Two years after that, he developed stage I laryngeal cancer of the glottis and received laser surgery, and since then he had been considered disease-free. He also had a history of hypertension, hypercholesterolemia, osteoporosis, and depression. His medications included aspirin, amlodipine, metoprolol succinate, valsartan, furosemide, simvastatin, insulin, prednisone, sirolimus, and sulfamethoxazole/trimethoprim. He was a married psychiatrist. He denied tobacco use and reported occasional alcohol use.The prolonged immunosuppressive therapy that is required following organ transplantation carries a markedly increased risk of the subsequent development of malignant tumors, including cancers of the lips and skin, lymphoproliferative disorders, and bronchogenic carcinoma. Primary brain lymphoma resulting in central diabetes insipidus would be unlikely in the absence of headache or focal weakne...

show abstract

Malignant lymphoma of bone

Cited by 296 publications

References 6 publications

Differentiating Lymphoblastic Lymphoma and Ewing's Sarcoma: Lymphocyte Markers and Gene Rearrangement

Differentiating Lymphoblastic Lymphoma and Ewing's Sarcoma: Lymphocyte Markers and Gene Rearrangement

True

A pain in the bone

Contact Info

Product

Resources

About